Clinical Trial

A Study of CM310 in Subjects With Moderate to Severe Asthma

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 4-week safety follow-up period.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-27.
Status change: Not Yet Recruiting → Recruiting 2023-12-14
Trial Details
NCT Number NCT05761028
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Moderate to Severe Asthma
Enrollment 600 participants
Start Date 2023-04-28
Primary Completion 2032-05 (estimated)
Study Completion 2032-05 (estimated)
Updated on ClinicalTrials.gov 2023-12-15